REGN Quantitative Stock Analysis

Validea's guru fundamental report indicates Regeneron Pharmaceuticals (REGN) rates highest under its Benjamin Graham Value Investor model, achieving a 71% score. While REGN demonstrates strong operational fundamentals, passing criteria for sales, debt, and long-term EPS growth, it notably fails on key valuation metrics such as P/E and Price/Book ratios, which are central to Graham's deep value methodology. This score falls below the 80% threshold typically indicating investor interest for this strategy, suggesting REGN's current valuation does not align with a strict deep value investment profile despite other underlying strengths.

Analysis

Regeneron Pharmaceuticals (REGN) scores 71% under Validea's investment model based on Benjamin Graham's deep value strategy, a score that falls below the 80% threshold which typically indicates interest from adherents to this methodology. The analysis reveals a dichotomy in the company's profile: while REGN exhibits strong operational health, passing criteria for sales, current ratio, and maintaining low long-term debt relative to net current assets, it fails on the core valuation metrics central to the Graham approach. Specifically, its Price-to-Earnings (P/E) and Price-to-Book (P/B) ratios are too high to qualify for a classic deep value screen. This suggests that despite solid long-term EPS growth and a healthy balance sheet, REGN's current market price does not offer the margin of safety that a strict Graham-style value investor would require.

Key Decisions for Investors

• Strict value investors should note that REGN fails to meet key valuation criteria (P/E and P/B) for a deep value strategy, suggesting its current price may not offer a sufficient margin of safety despite strong underlying fundamentals.
• Investors with a Growth at a Reasonable Price (GARP) or growth-oriented focus may find the company's strengths in sales, low debt, and long-term EPS growth attractive, but must be comfortable with a valuation that is considered elevated by value standards.
• A potential entry point for value-oriented portfolios could emerge if REGN's valuation multiples contract without a corresponding deterioration in its fundamental metrics; therefore, monitoring its P/E and P/B ratios is prudent.